By expenditures
| Name | Title | Type |
|---|---|---|
| Tammy Betancourt | Chief Financial Officer/Vp Of Finance | Auditee |
| Sara McKenna | Senior Manager | Auditee |
| Matthew Schueler | Partner | Auditee |
| Chris J Suda | Principal | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 395941 | 2025 | 2026-03-30 | CLIFTONLARSONALLEN LLP | $6.46M |
| 332657 | 2024 | 2024-12-16 | Cliftonlarsonallen LLP | $6.20M |
| 15128 | 2023 | 2024-02-01 | Wipfli LLP | $6.49M |
| 49021 | 2022 | 2023-01-10 | Wipfli LLP | $8.47M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 395941 | 2025 | 2026-03-30 | 1201290 | 2025-003 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201289 | 2025-003 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201288 | 2025-002 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201287 | 2025-002 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201286 | 2025-002 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201285 | 2025-002 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201284 | 2025-001 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201283 | 2025-001 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201282 | 2025-001 | Material Weakness | Yes | N |
| 395941 | 2025 | 2026-03-30 | 1201281 | 2025-001 | Material Weakness | Yes | N |
| 332657 | 2024 | 2024-12-16 | 1090827 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090826 | 2024-003 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090825 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090824 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 1090823 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090822 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090821 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 1090820 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090819 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090818 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 1090817 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090816 | 2024-003 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090815 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 1090814 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 514385 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514384 | 2024-003 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514383 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514382 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 514381 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514380 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514379 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 514378 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514377 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514376 | 2024-001 | Material Weakness | - | N |
| 332657 | 2024 | 2024-12-16 | 514375 | 2024-004 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514374 | 2024-003 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514373 | 2024-002 | Significant Deficiency | - | N |
| 332657 | 2024 | 2024-12-16 | 514372 | 2024-001 | Material Weakness | - | N |